|
|
|
|
News
|
Delegates from the Chinese Ministry of Science and Technology Discuss Opportunities for Collaboration with Gladstone
In November 2007, Gladstone was honored to host a delegation from the Chinese Ministry of Science and Technology. Bob Mahley, Deepak Srivastava, Lennart Mucke, Fen-Biao Gao, Li Gan, and Erik Roberson were among the Gladstone scientists attending. Yadong Huang and Karl Weisgraber presented overviews of Gladstone's science and discussed ways that Gladstone can expand its interactions with China.
Among the opportunities cited were a Chinese version of the Turkish Heart study in Western China and an extension of the discussions already begun with GIND's Asia initiative for Alzheimer's disease.
The visit was a result of the efforts of Advisory Council member Sue Siegel, whose former company, Affymetrix, has had a strategic relationship with China for the last 4 years. Gladstone and Mission Bay were the only stops for the delegation on the West Coast.
Treating AIDS
Global HIV/AIDS Medicine, a comprehensive textbook on the clinical treatment of AIDS, was recently published. Management of HIV/AIDS differs around the world, and this textbook is the first to address the many clinical difficulties faced by healthcare providers worldwide. The editors include GIVI director Warner Greene.
|
|
|
|
Jimmy Carter Attends PhD Seminar at Gladstone
In December 2007, Sarah Carter (pictured below, fourth from the left, with members of her family) completed her PhD thesis research in the laboratory of GIND investigator Steven Finkbeiner. She described that research in a final seminar that was attended by several members of her family, including her parents and her grandparents, former President Jimmy Carter and Rosalyn Carter.
Alzheimer’s Disease Research to Be Featured on KQED’s QUEST
San Francisco public television station KQED's innovative science series QUEST begins its second season in February with a story on Gladstone research on APOE 4 and Alzheimer's disease set to air in April.
|
|
Robert Mahley and his team from the Center for Translational Research participated in 2 days of
|
|
filming for the story in November. Gladstone is proud to be a partner of the QUEST program and participates in story planning and an emerging educational outreach effort. For more information, visit www.kqed.org/quest.
|
Merle Sande Memorial Lecture Scheduled for February
The annual Merle Sande Lecture, sponsored by the Gladstone Institute of Virology and Immunology, will be delivered on Friday, February 8, 2008, in the Robertson Auditorium in the Rutter Center, UCSF Mission Bay campus. The speaker will be Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases (NIAID) and Chief of the NIAID Laboratory of Immunoregulation.
|
|
Dr. Fauci's lecture is titled HIV/AIDS in 2008: Progress and Challenges.
Dr. Warner Greene recently described the heroic work and spirit of Dr. Sande, who died on November 14, 2007, in his home in Seattle, Washington:
“We hold the annual Merle Sande Lecture at the Gladstone Institute of Virology and
|
Immunology. Regrettably, from this day forward, this lecture will be renamed as the Merle Sande Memorial Lecture. Throughout his professional life, Merle was a shining example for the legions of young clinicians and scientists whose lives he touched in so many magical ways. Each of us is now left with our individual memories of Merle, but hopefully challenged with helping to complete his life's work. His legacy is storied, but the final chapters of the Merle Sande book are not yet written. Today, I and his many friends and colleagues rededicate our efforts to realizing his dream of an African continent free of threat of HIV/AIDS.”
|
|
|
|
Gilead Sciences, Inc., and the Gladstone Institute of Virology and Immunology (GIVI) have announced a multi-year research collaboration focusing on the HIV Vif protein. Vif promotes destruction of a potent host antiviral factor which is critical for the effective growth and spread of the virus in infected patients. Gilead will collaborate with the laboratory of GIVI director Warner C. Greene in these studies.
Groundbreaking work in Dr. Greene's lab revealed that Vif interferes with the potent antiviral function of a naturally occurring cellular factor APOBEC3G (A3G), which if incorporated into budding HIV virions causes lethal mutations in the virus that blocks its ability to grow in the next cell.
Under the agreement, Gilead will provide undisclosed research support as well as downstream royalty payments and milestone fees on inhibitors of Vif action resulting from the collaboration.
“If we are able to successfully target Vif, we can re-enable the potent antiviral activity of APOBEC3G. Such agents would represent an entirely new class of HIV antiviral drugs,” Dr. Greene said. “We are looking forward to a stimulating and productive collaboration with Gilead, which has been a leader in HIV drug development.”
“Gilead is very enthusiastic about our partnership with the Gladstone Institute of Virology and Immunology and Dr. Greene to investigate a novel mechanism of targeting HIV disease,” commented William Lee, PhD, senior vice president, Research for Gilead Sciences. “Although much progress has been made in the treatment of HIV and AIDS, ongoing research is necessary to ensure a next generation of medications to combat the virus.”
|
|
TOP
|
|
|
|
|
|
